Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Marketwired

11:18 EDT 18th June 2018 | BioPortfolio

Here are the most relevant search results for "Marketwired" found in our extensive news archives from over 250 global news sources.

More Information about Marketwired on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Marketwired for you to read. Along with our medical data and news we also list Marketwired Clinical Trials, which are updated daily. BioPortfolio also has a large database of Marketwired Companies for you to search.

Showing News Articles 1–25 of 9,800+ from Marketwired

Monday 30th April 2018

Savara to Host First Quarter 2018 Financial Results and Business Update Conference Call on Wednesday, May 9, 2018

AUSTIN, TX--(Marketwired - May 01, 2018) - Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced it will release its first quarter 2018 financial results on Wednesday, May 9, 2018. Savara management will also host a conference call for investors beginning at 5:30 p.m. ET on Wednesday, May 9, 2018 to discuss its first quarter 2018 financial results and to provide a business u...

Pieris Pharmaceuticals to Host First Quarter 2018 Investor Call and Corporate Update on May 10, 2018

BOSTON, MA--(Marketwired - May 01, 2018) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it will host a first quarter 2018 investor call on Thursday, May 10, 2018 at 8:00 AM (EDT) to discuss financial results and provide a c...

NeoGenomics Reports Revenue of $63.4 Million, Net Income of $0.6 Million and Adjusted EBITDA of $9.2 Million in the First Quarter of 2018

FT. MYERS, FL--(Marketwired - May 01, 2018) - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the first quarter 2018. First Quarter 2018 Highlights: Consolidated revenues for the first quarter of 2018 were $63.4 million, an increase of 10.4% over the same period in 2017. After adjusting 2017 results for the divestitur...

Sunday 29th April 2018

VIVUS Strengthens Executive Leadership Team

CAMPBELL, CA--(Marketwired - April 30, 2018) - VIVUS,Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company, today announced the addition of three executives to the Company's senior leadership team. John Amos has joined as the Company's new Chief Executive Officer and a new member of the Company's Board of Directors. Scott Oehrlein is Chief Operations Officer, a newly created position wi...

Advanzeon Solutions, Inc. Expands Management Team and Presence in California

TAMPA, FL--(Marketwired - April 30, 2018) - Advanzeon Solutions, Inc. (OTCBB: CHCR) ("Advanzeon" or the "Company") announced today that it has expanded its management team by electing Dr. Stephen Kreitzer, currently serving as the Company's Medical Director, to the Company's Board of Directors; electing Dr. Arnold Finestone, a current member of the Company's Board of Directors and longstanding Cha...

FDA Authorizes CTD to Proceed with Extension Protocol to US Phase I Trappsol(R) Cyclo(TM) Trial for Niemann-Pick Disease Type C

ALACHUA, FL--(Marketwired - April 30, 2018) - CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that FDA has authorized its application for "An Open-Label Extension Study of the Long-Term Safety and Efficacy of Intravenous Trappsol® Cyclo™ (HPBCD) in Patients w...

Thursday 26th April 2018

Advanzeon Solutions, Inc. to File 10-K for 2013 and 2014

TAMPA, FL--(Marketwired - April 27, 2018) - Advanzeon Solutions, Inc. (OTCBB: CHCR) ("Advanzeon or the "Company") announced today that it anticipates filing its Annual Report on Form 10-K ("10-K") for the fiscal years ending 2013 and 2014 by May 9, 2018. Clark A. Marcus, the Company's Chairman and CEO, stated, "Approximately one and half years ago, the Company retained the services of outside in...

Wednesday 25th April 2018

Moleculin Announces New Data for Immuno-Stimulating Drug to be Presented at International Conference

HOUSTON, TX--(Marketwired - April 26, 2018) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that Dr. Waldemar Priebe, Chair of the Comp...

Oncolytics Biotech(R) Announces Details of 2018 Annual General Meeting of Shareholders

CALGARY, AB and SAN DIEGO, CA--(Marketwired - April 26, 2018) - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that its 2018 Annual General Meeting of Shareholders will be held on Thursday, May 3rd, 2018 at 4:30 pm ET at the Toronto Region Board of Trade lo...

Tuesday 24th April 2018

VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Tuesday, May 8, 2018

CAMPBELL, CA--(Marketwired - April 25, 2018) - VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2018 after the market close on Tuesday, May 8, 2018. The company will host a conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT the same day to review results and provide a business update. To listen via webcas...

Robert A. Essner, former Chairman and Chief Executive of Wyeth, named Executive Chairman of Elucida Oncology, Inc.

NEW YORK, NY--(Marketwired - April 25, 2018) - ELUCIDA ONCOLOGY, INC®, a biotechnology company focused on developing and commercializing a first-in-class, ultra-small nanoparticle platform technology for the diagnosis and treatment of cancer, announced today that it has appointed Robert A. Essner as its Executive Chairman. Mr. Essner was Chairman and Chief Executive Officer for Wyeth, acquired by...

Pieris Pharmaceuticals Appoints Ann Barbier, M.D., Ph.D., to its Board of Directors

BOSTON, MA--(Marketwired - April 25, 2018) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that Dr. Ann Barbier has joined the Company's Board of Directors. Dr. Barbier is currently the Chief Medical Officer of Tr...

Monday 23rd April 2018

Moleculin Enters Agreement with BSP Pharmaceuticals for its Leukemia Drug Candidate

HOUSTON, TX--(Marketwired - April 24, 2018) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that it has entered into an agreement to e...

Tetra Bio-Pharma Signs Landmark Commercialization Term Sheet for its Lead Pharmaceutical Product, PPP001, in Israel

OTTAWA, ONTARIO -- (Marketwired) -- 04/24/18 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP) (OTCQB: TBPMF), announced today that the Company has signed a first binding term sheet for the marketing and distribution of PPP001 in Israel with Kamada Ltd., a leading pharmaceutical company. The signing of a Definitive Distribution Agreement is expected to follow shortly. PPP001...

Avalon GloboCare Forms Joint Laboratory with Top-Ranked Hospital in Shanghai for Regenerative Exosomics

FREEHOLD, NJ--(Marketwired - April 24, 2018) - Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that the Company's subsidiary, GenExosome Technologies Inc., has formed a joint laboratory for regenerative exosomics with the Shanghai Ninth People's Hospital (SNPH), a top-ranked medical institute in China and the Asia Pacific region, renown...

Sunday 22nd April 2018

CTD Holdings Closes $2.00 Million Private Placement

ALACHUA, FL--(Marketwired - April 23, 2018) - CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that it has closed a private placement of its securities with a group of accredited investors that included several directors of the Company and members of management. I...

Wednesday 18th April 2018

CTD Holdings Finalizes Cooperative Agreement for Alzheimer's Disease Research Program

ALACHUA, FL--(Marketwired - April 19, 2018) - CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has finalized a cooperative research agreement with Kerwin Research Center, LLC to explore the use of cyclodextrins in the treatment of Alzheimer's dise...

Tuesday 17th April 2018

Oncolytics Biotech(R) Demonstrates Positive Data in Two Posters at AACR Annual Meeting 2018

CALGARY, AB and SAN DIEGO, CA--(Marketwired - April 18, 2018) - - Preclinical models proved pelareorep increased PD-L1 expression in microsatellite stable (MSS) colorectal cancer cells (CRC) - - Demonstrated efficacy of pelareorep and anti-PD1 agent combination - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-...

Monday 16th April 2018

Oncolytics Biotech(R) Announces Management Change

CALGARY, AB and SAN DIEGO, CA--(Marketwired - April 17, 2018) - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus creating an inflamed phenotype, today announced that Andres Gutierrez, Chief Medical Officer at Oncolytics, will be leaving to pursue other opportunities, effective April 23, 2018. "Doct...

Wednesday 11th April 2018

Tetra Bio-Pharma Clinical Study on Cannabis Oil Capsules for Patients Suffering from Chronic Pain should be completed by Fall 2018

OTTAWA, ONTARIO -- (Marketwired) -- 04/12/18 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP) (OTCQB: TBPMF), provides a status report on its encapsulated cannabis oils (PPP005) clinical trials and that these cannabis products are ready to commercialize in the retail market post-legalization. Natural health products and OTC medications The authorization from the Office of...

Monday 9th April 2018

VistaGen Therapeutics Receives European Patent regarding Methods of Production for AV-101

SOUTH SAN FRANCISCO, CA--(Marketwired - April 10, 2018) - VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced the European Patent Office has issued a Notice of Intention to grant a patent related to certain methods of production for AV-101, the Co...

Tetra Bio-Pharma Announces the appointment of Gregory Drohan to its board of directors

OTTAWA, ONTARIO -- (Marketwired) -- 04/10/18 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that it has appointed Gregory Drohan to its board of directors effective April 10, 2018. The company will nominate Mr. Drohan for election at Tetra's 2018 Annual Meeting of Sharehol...

Milestone Scientific Announces Appointment of Eric Gilbert as Vice President of US Sales

LIVINGSTON, NJ--(Marketwired - April 10, 2018) - Milestone Scientific Inc. (NYSE American: MLSS) (NYSE MKT: MLSS), a leading developer of computerized drug instruments that provide painless and precise injections, today announced the appointment of Eric W. Gilbert as Vice President of US Sales. Eric Gilbert brings extensive experience in medical instruments sales, including extensive experience w...

Oncolytics Biotech(R) Presents Positive REOLYSIN(R) Data in Combination with Keytruda and anti-CD73 at International Oncolytic Virus Conference 2018

CALGARY, AB and SAN DIEGO, CA--(Marketwired - April 10, 2018) - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus creating an inflamed phenotype, today announced that a poster highlighting the effectiveness of pelareorep in combination with Keytruda® and/or an anti-CD73 immunotherapy in prostate can...

Sunday 8th April 2018

Cerecor Appoints Simon Pedder to its Board of Directors

BALTIMORE, MD--(Marketwired - April 09, 2018) - Cerecor, Inc. (NASDAQ: CERC), today announced that Simon C. Pedder, Ph.D. has been appointed to its Board of Directors. "We are delighted to welcome Dr. Pedder to our Board." said Dr. Uli Hacksell, Chairman of the Board of Cerecor, "With his experience in all stages of drug development and collaborating with the FDA on several products leading to a...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks